Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
Background: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown.Patien...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.01315/full |
| _version_ | 1819181938796134400 |
|---|---|
| author | Yujie Lu Yiwei Tong Jiahui Huang Lin Lin Jiayi Wu Xiaochun Fei Ou Huang Jianrong He Li Zhu Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen |
| author_facet | Yujie Lu Yiwei Tong Jiahui Huang Lin Lin Jiayi Wu Xiaochun Fei Ou Huang Jianrong He Li Zhu Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen |
| author_sort | Yujie Lu |
| collection | DOAJ |
| description | Background: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown.Patients and Methods: Consecutive breast cancer patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital between January 2009 and December 2018 were retrospectively analyzed. Patients with available 21-gene RS result for the primary tumor and reporting disease recurrence during follow-up were included. Association of 21-gene RS and overall survival (OS), post-recurrence overall survival (PR-OS), post-recurrence progression-free survival (PR-PFS), and first-line systemic treatment after recurrence were compared among different groups.Results: A total of 74 recurrent patients were included, with 10, 27, 37 patients in the RS <18, 18–30, and ≥ 31 groups, respectively. Recurrent patients with RS ≥ 31 were more likely to receive chemotherapy as their first-line treatment compared to those with RS <31 (P = 0.025). Compared to those with RS <31, patients with RS ≥ 31 had significantly worse OS (P = 0.025), worse PR-OS (P = 0.026), and a trend of inferior PR-PFS (P = 0.106). Multivariate analysis demonstrated that primary ER expression level (OS: P = 0.009; PR-OS: P = 0.017) and histological grade (OS: P = 0.003; PR-OS: P = 0.009), but not primary 21-gene RS (OS: P = 0.706; PR-OS: P = 0.120), were independently associated with worse OS and PR-OS.Conclusions: High primary 21-gene RS tended to be associated with worse disease outcome in loco-regional and distant recurrent breast cancer patients, which could influence the first-line systemic treatment after relapse, warranting further clinical evaluation. |
| first_indexed | 2024-12-22T22:38:11Z |
| format | Article |
| id | doaj.art-30b7e910142a43cc88686ddf5cebc350 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-22T22:38:11Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-30b7e910142a43cc88686ddf5cebc3502022-12-21T18:10:15ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-07-011010.3389/fonc.2020.01315547495Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer PatientsYujie Lu0Yiwei Tong1Jiahui Huang2Lin Lin3Jiayi Wu4Xiaochun Fei5Ou Huang6Jianrong He7Li Zhu8Weiguo Chen9Yafen Li10Xiaosong Chen11Kunwei Shen12Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBackground: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown.Patients and Methods: Consecutive breast cancer patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital between January 2009 and December 2018 were retrospectively analyzed. Patients with available 21-gene RS result for the primary tumor and reporting disease recurrence during follow-up were included. Association of 21-gene RS and overall survival (OS), post-recurrence overall survival (PR-OS), post-recurrence progression-free survival (PR-PFS), and first-line systemic treatment after recurrence were compared among different groups.Results: A total of 74 recurrent patients were included, with 10, 27, 37 patients in the RS <18, 18–30, and ≥ 31 groups, respectively. Recurrent patients with RS ≥ 31 were more likely to receive chemotherapy as their first-line treatment compared to those with RS <31 (P = 0.025). Compared to those with RS <31, patients with RS ≥ 31 had significantly worse OS (P = 0.025), worse PR-OS (P = 0.026), and a trend of inferior PR-PFS (P = 0.106). Multivariate analysis demonstrated that primary ER expression level (OS: P = 0.009; PR-OS: P = 0.017) and histological grade (OS: P = 0.003; PR-OS: P = 0.009), but not primary 21-gene RS (OS: P = 0.706; PR-OS: P = 0.120), were independently associated with worse OS and PR-OS.Conclusions: High primary 21-gene RS tended to be associated with worse disease outcome in loco-regional and distant recurrent breast cancer patients, which could influence the first-line systemic treatment after relapse, warranting further clinical evaluation.https://www.frontiersin.org/article/10.3389/fonc.2020.01315/fullbreast cancer21-gene RSrecurrenceprognosisfirst-line treatment |
| spellingShingle | Yujie Lu Yiwei Tong Jiahui Huang Lin Lin Jiayi Wu Xiaochun Fei Ou Huang Jianrong He Li Zhu Weiguo Chen Yafen Li Xiaosong Chen Kunwei Shen Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients Frontiers in Oncology breast cancer 21-gene RS recurrence prognosis first-line treatment |
| title | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients |
| title_full | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients |
| title_fullStr | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients |
| title_full_unstemmed | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients |
| title_short | Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients |
| title_sort | primary 21 gene recurrence score and disease outcome in loco regional and distant recurrent breast cancer patients |
| topic | breast cancer 21-gene RS recurrence prognosis first-line treatment |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.01315/full |
| work_keys_str_mv | AT yujielu primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT yiweitong primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT jiahuihuang primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT linlin primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT jiayiwu primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT xiaochunfei primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT ouhuang primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT jianronghe primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT lizhu primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT weiguochen primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT yafenli primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT xiaosongchen primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients AT kunweishen primary21generecurrencescoreanddiseaseoutcomeinlocoregionalanddistantrecurrentbreastcancerpatients |